Fox Business Apr. 07, 2021 – 5:06 – NeuroRX CEO Dr. Jonathan Javitt discusses the new COVID-19 drug for respiratory distress and vaccine boosters.
Cheddar News – Apr 2, 2021 02:23 pm
Interview with Dr. Yo – Streamed live on Feb 11, 2021
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.
A drug that mimics a peptide produced by the bowel has been fast-tracked by the Food and Drug Administration to treat COVID-19 lung inflammation, NeuroRx Inc. announced Wednesday. The drug protects cells believed to act as a gateway for the coronavirus to attack the lungs.
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
University of Miami Health System
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19.